Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 113.4% in December

Akari Therapeutics, Plc (NASDAQ:AKTX) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 144,500 shares, an increase of 113.4% from the December 15th total of 67,700 shares. Based on an average daily trading volume, of 109,400 shares, the short-interest ratio is currently 1.3 days.

Shares of NASDAQ AKTX opened at $1.45 on Friday. Akari Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $4.21. The company has a 50 day simple moving average of $1.55 and a two-hundred day simple moving average of $1.64. The company has a market capitalization of $75.27 million, a price-to-earnings ratio of -2.84 and a beta of 1.26.

Akari Therapeutics (NASDAQ:AKTX) last announced its earnings results on Friday, December 3rd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter.

Several hedge funds and other institutional investors have recently made changes to their positions in AKTX. HighTower Advisors LLC bought a new position in shares of Akari Therapeutics during the second quarter valued at approximately $45,000. Renaissance Technologies LLC increased its stake in shares of Akari Therapeutics by 14.0% during the second quarter. Renaissance Technologies LLC now owns 151,396 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 18,645 shares in the last quarter. Citadel Advisors LLC increased its stake in shares of Akari Therapeutics by 88.6% during the second quarter. Citadel Advisors LLC now owns 52,265 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 24,553 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Akari Therapeutics during the third quarter valued at approximately $25,000. 2.56% of the stock is owned by institutional investors and hedge funds.

About Akari Therapeutics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Featured Article: What does cost of debt say about a company’s financial health?

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.